Relevant and even prescient commentary on news, politics and the economy.

Politics and Power of a Tweet Depends on Who You Are

With all the crap, trump has said in tweeting over 4 years which equates to > 20,000 tweets  via “Wiki,” I find it to be infantile and a double standard for Manchin, Collins, and Romney to call Neera Tandern out for her tweets. Where were they over the last 4 years of trump, hiding from him perhaps?

Joe Manchin has a bone to pick with Neera Tanden

And its personal. The background;

“Office of Management and Budget director nominee Neera Tanden previously sent a tweet taking issue with the salary of former (retired in 2020) CEO of the pharmaceutical company Mylan, Heather Bresch, who is the daughter of Senator Joe Manchin (D-WV).”

In August 2016, Neera Tanden shared a screengrab of an article about Bresch which focused on a significant rise in her pay while at Mylan. It highlighted that the company’s board said this was justified as she had “contributed significantly to the company’s growth in recent years.”

“The idea that only CEO contributes to a company’s growth and not all employees is really pernicious.”

The company headlines may be correct. A little background from an earlier 2019 post of mine :

The new Pittsburgh – based unnamed company is expected to be among the world’s largest sellers of generic and off-patent medicines with more than $19 billion in yearly sales. Pfizer Shareholders will own 57% of the new company and Mylan shareholders would the rest. Pfizer would be paid $12 billion raised from new debt acquired from the joint venture. Upjohn would return to the US from its corporate base in Shanghai, a reversal of its earlier inversion.

To me, this is a strategic move along the lines of Pfizer selling off the marketing of EpiPen to Mylan and keeping the manufacturing of it. Pfizer owned Meridian Medical Technologies manufactured EpiPen for Mylan and it will now be a part of the sale to Mylan. EpiPen was a huge success story for Mylan. A quadrant strategy of milking of a cash cow to fund new ventures.